Danger with Hydroxychloroquine Nonadherence in SLE A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality. https://t.co/RFPQZXQMeI https://t.co/eu1rhVyV18

SLE and Pregnancy Outcomes Obstetric complications and poor pregnancy outcomes are not uncommon in women with systemic lupus erythematosus (SLE), especially with active disease. https://t.co/BeCQYTq928 https://t.co/M6oILWfah1

EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. https://t.co/KYLBU3E0k6 https://t.co/oHgqEX8Gr6

Belgian study of 312 PsA & 213 SpA pts showed that most had normal spinal Xrays (87.5% PsA, 92% SpA). SpA pts had higher mSASSS than PsA (p<0.05). More Cx (73%) than Lumbar (33%) in PsA; SpA, CX (64%) & LS (71%) evenly distributed https://t.co/Z8JRRuxmWZ https://t.co/8uMiAsk7aA

Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/j4Cd42akx6 https://t.co/rQ6vZRw34A

Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh

Combination Cannabidiol (CBD) & hydroxychloroquine in RA? A phase II trial of IHL-675A (CBD+HCQ) will soon begin; following on phase I and animal studies showing it was tolerated, with no adverse events of concern.IHL-675A was superior to HCQ alone. https://t.co/HZYR7FA7i1 https://t.co/jvlot0OIw4

Nonprofit Allen Institute for Immunology will partner with researchers from Eli Lilly to investigate and profile disease state diversity and biomarkers for drug response in atopic dermatitis and rheumatoid arthritis https://t.co/nRbdWdFx7C https://t.co/rlngbtxgUo

Research from 12 states with medical cannabis laws looked at 583 820 adults w/ chronic noncancer pain. Data over 3 yres shows < 0.05% change in the use of opioid prescriptions, nonopioid prescriptions, pain meds, or chr pain procedures https://t.co/ArbP4xe4dH https://t.co/MPRBZNIIoS

Top 10-selling drugs accts for 22% of Medicare part D spending ($47.7/$215.7 billion) Eliquis $12.6 Billion Trulicity $4.7 B Januvia $4.1B Jardiance $3.7B Lantus $2.8B Ozempic $2.6B Revlimid $5.9B Xarelto $5.2B Imbruvica $3.2B Humira $2.9B https://t.co/5rvLldNLF0 https://t.co/OOt8he8Ig4

In AUSTRALIA, 30% (~ 7million) have a chronic #MSK condition, costing $14.6 billion (10% of all healthcare spending) in 2019-20. Overall, 4 million w/ back problems, 3 million arthritis, 900,000 osteoporosis, 450,000 w/ #RA. https://t.co/TDV50PoRXj https://t.co/EtSUuv6jMA

Filgotinib Effects on Semen and Sex Hormones The oral Janus kinase 1 inhibitor filgotinib is available worldwide, but not in the USA, where the FDA held up its approval for use in RA due to unfinished studies of filgotinib's effects on sperm cells. https://t.co/SrwInSY45G https://t.co/TD54PXNFbi